BRIEF-Trillium Therapeutics' TTI-621 receives FDA clearance to proceed in clinical trial

Wed Aug 17, 2016 7:26am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Aug 17 (Reuters) - Trillium Therapeutics Inc

* Trillium Therapeutics receives FDA clearance to proceed with TTI-621 in clinical trial targeting solid tumors and mycosis fungoides Source text for Eikon: Further company coverage: